Tempus AI, Inc.\u00a0TEM reported a second-quarter\u00a02025 adjusted loss of 22 cents per share, narrower than the Zacks Consensus Estimate by 4.35%.<\/p>\n
GAAP loss per share was 25 cents compared with a loss of $6.86 year over year.<\/p>\n
TEM\u2019s Q2 Revenues<\/p>\n
Revenues totaled $314.6 million, which beat the Zacks Consensus Estimate by 5.12%. The top line surged 89.6% on a year-over-year basis.<\/p>\n
Following the announcement, shares of Tempus AI rose 2.2% in the pre-market trading today.<\/p>\n
Detailed Breakdown of TEM\u2019s Q2 Revenues<\/p>\n
In the second quarter, Genomics contributed $193.8 million in revenues, up 115.3% year over year.<\/p>\n
Within this, Oncology testing (legacy Tempus clinical) revenues were $133.2 million, up 32.9% year over year. This was supported by approximately 26% volume growth in the second quarter.<\/p>\n
Tempus AI, Inc. Price, Consensus and EPS Surprise<\/p>\n
Tempus AI, Inc. price-consensus-eps-surprise-chart | Tempus AI, Inc. Quote<\/p>\n
Hereditary testing (legacy Ambry Genetics) contributed $97.3 million in revenues, up 33.6% year over year on a pro-forma basis. Volume growth was approximately 32%.<\/p>\n
The Data and Services product line reported sales of $72.8 million, up 35.7% year over year. This was driven by Insights (data licensing), which grew 40.7% year over year.<\/p>\n
TEM\u2019s Margin Performance<\/p>\n
The gross profit in the quarter totaled $195 million, up 158.3% from the year-ago quarter\u2019s level. The adjusted gross margin expanded 1649 bps to 62% despite a 32.2% rise in the cost of revenues (genomics, data and services).<\/p>\n
Total adjusted operating expenses were $256.8 million, down 57.8% from the year-ago quarter\u2019s level.<\/p>\n
TEM\u2019s Liquidity Position<\/p>\n
At the end of the second quarter of 2025, the company had cash and cash equivalents of $186.3 million compared with $151.6 million at the end of the first quarter.<\/p>\n
Cumulative net cash used in operating activities at the end of the second quarter was $61.46 million compared with an outflow of $198.5 million in the prior year.<\/p>\n
Tempus AI\u2019s Full-Year Outlook<\/p>\n
The company provided updated guidance for 2025. Full-year revenues are expected to be approximately $1.26 billion (earlier $1.25 billion) for the consolidated Tempus and Ambry Genetics business, indicating nearly 82% annual growth. The Zacks Consensus Estimate for TEM\u2019s revenues in 2025 currently stands at $1.24 billion.<\/p>\n
Adjusted EBITDA for the year is expected to be $5 million, an improvement of approximately $110 million over 2024.<\/p>\n
Our Take on TEM Stock<\/p>\n
Tempus AI ended the second quarter of 2025 with better-than-expected earnings and revenues. The company witnessed a significant reacceleration of its clinical volumes. The company had several milestones in the second quarter, including the introduction of Tempus xM for treatment and response monitoring, a liquid biopsy assay designed to monitor immunotherapy response in patients with advanced solid tumors. It also extended the Tempus Next care pathway intelligence platform into breast cancer, furthering AI-driven decision support across oncology. Furthermore, raised revenue guidance for the year bodes well for the stock.<\/p>\n
TEM\u2019s Zacks Rank and Key Picks<\/p>\n
Tempus AI currently carries a Zacks Rank #3 (Hold).<\/p>\n
Some better-ranked stocks from the broader medical space are Medpace Holdings MEDP, GeneDx Holdings WGS and Boston Scientific BSX.<\/p>\n
Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today\u2019s Zacks #1 Rank stocks here.<\/p>\n
MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite\u2019s 10.1% growth. The company surpassed earnings estimates in each of the trailing four quarters, with the average surprise being 13.87%.<\/p>\n
GeneDx Holdings, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter 2025 adjusted EPS of 50 cents, exceeding the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%.<\/p>\n
WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry\u2019s 18.6% growth. The company\u2019s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 231.40%.<\/p>\n
Boston Scientific, currently carrying a Zacks Rank #2, reported a second-quarter 2025 adjusted EPS of 75 cents, which topped the Zacks Consensus Estimate by 4.2%.<\/p>\n
BSX has a historical five-year earnings growth rate of 13.3% compared with the industry\u2019s 2.7% growth. The company\u2019s earnings beat estimates in each of the trailing four quarters, with the average surprise being 8.11%.<\/p>\n
This article originally published on Zacks Investment Research (zacks.com).<\/p>\n
Zacks Investment Research<\/p>\n","protected":false},"excerpt":{"rendered":"Tempus AI, Inc.\u00a0TEM reported a second-quarter\u00a02025 adjusted loss of 22 cents per share, narrower than the Zacks Consensus…\n","protected":false},"author":2,"featured_media":2398,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[200,79],"class_list":["post-68015","post","type-post","status-publish","format-standard","has-post-thumbnail","category-genetics","tag-genetics","tag-science"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/68015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=68015"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/68015\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/2398"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=68015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=68015"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=68015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}